Bank of America Corp DE has $40.18 million stock Holdings in Cogent Biosciences, Inc. $COGT. August 14, 2026 Key points. * Bank of America reduced its Cogent Biosciences stake by 12.6% in the first quarter, selling 150,125 shares and retaining 1,043,805 shares valued at approximately $40.18 million, or 0.61% of the company. * Cogent shares opened at $37.31, down 4.3%, with a market capitalization of $6.47 billion. The company reported a quarterly loss of $0.52 per share, beating analyst expectations of a $0.55 loss. * Analyst sentiment remains generally positive: Cogent has a "Moderate Buy" consensus rating and an average price target of $49.10, despite ratings ranging from "Strong Buy" to "Sell." * MarketBeat previews top five stocks to own in September. Bank of America Corp DE reduced its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 12.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,043,805 shares of the technology company's stock after selling 150,125 shares during the period. Bank of America Corp DE owned approximately 0.61% of Cogent Biosciences worth $40,176,000 as of its most recent filing with the Securities and Exchange Commission. Several other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its position in Cogent Biosciences by 1,164.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company's stock valued at $25,000 after acquiring an additional 652 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company's stock worth $33,000 after buying an additional 1,333 shares during the period. Strs Ohio acquired a new stake in Cogent Biosciences during the 1st quarter worth about $36,000. Global Retirement Partners LLC bought a new stake in Cogent Biosciences in the fourth quarter worth approximately $37,000. Finally, Parallel Advisors LLC acquired a new position in shares of Cogent Biosciences during the 1st quarter valued at $39,000. Cogent Biosciences stock down 4.3%. COGT stock opened at $37.31 on Friday. The company has a quick ratio of 15.14, a current ratio of 15.14 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $6.47 billion, a PE ratio of -17.27 and a beta of 0.38. Cogent Biosciences, Inc. has a twelve month low of $11.41 and a twelve month high of $43.73. The stock has a 50-day simple moving average of $37.87 and a two-hundred day simple moving average of $36.65. Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.03. On average, equities analysts predict that Cogent Biosciences, Inc. will post -2.2 EPS for the current fiscal year. Analyst ratings changes. A number of equities research analysts recently weighed in on the stock. Wedbush restated an "outperform" rating and issued a $55.00 target price on shares of Cogent Biosciences in a report on Friday, May 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. HC Wainwright increased their price objective on Cogent Biosciences to $55.00 and gave the stock a "buy" rating in a research note on Wednesday, May 6th. Finally, Guggenheim raised their target price on Cogent Biosciences from $45.00 to $52.00 and gave the company a "buy" rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $49.10. Discover more Stock ratings screener ETF screener access Cogent Biosciences company profile. Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company's research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments. The company's lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Cogent Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list. While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Cogent Biosciences presented detailed Phase 3 PEAK trial data at the 2026 ASCO annual meeting, showing bezuclastinib combined with sunitinib achieved median progression-free survival of 16.5 months versus 9.2 months for sunitinib alone in gastrointestinal stromal tumour patients (HR=0.50, p<0.0001). This marks the first treatment to demonstrate statistically significant advantage against an active comparator in GIST patients. The combination showed clear benefit across all mutational subgroups, with mean treatment duration of 21.4 months. The safety profile was consistent with sunitinib alone, with no unique risks observed. The FDA granted Priority Review for the bezuclastinib combination in GIST patients previously treated with imatinib, with a PDUFA date of 30 November 2026. Cogent has initiated a new trial in first-line GIST patients.

Cogent Biosciences reported a wider Q1 2026 net loss of $97.35 million as the biotech company increased spending on regulatory and launch preparation for bezuclastinib. The loss follows a remarkable one-year shareholder return of approximately seven times, though year-to-date returns have moderated to 3.25%. The company trades at a price-to-book ratio of 11.3 times, substantially above the US biotechs industry average of 2.3 times, reflecting investor optimism about bezuclastinib's potential. However, Cogent remains pre-revenue with net losses of $354.3 million, making its valuation heavily dependent on analyst forecasts of rapid revenue growth and profitability within three years. Shares recently declined 3% to $35.87, suggesting investor caution around elevated spending against the backdrop of future execution risks.